Standalone Sandoz And Biocon’s Biosimilars: 2022’s Biggest Deals
Apotex Moves From Family To Private Equity, Among Other Transactions
The acquisition and consolidation mania that gripped industry in the middle half of the last decade may seem like a distant dream but players continued to spend cash where it could be justified in 2022, while raising much-needed capital to fund their endeavors.
You may also be interested in...
Biocon Closes $3bn Deal For Viatris Biosimilars
Biocon has achieved a milestone after its Biocon Biologics subsidiary closed its $3bn deal to acquire the biosimilars business of longtime partner Viatris, in what management described as a “historic inflection point” for the Indian player.
Alvotech Acquires Reykjavik Manufacturing Facility Amid $136m Financing Boost
Months after it become a public company, Alvotech has once again turned to the debt/equity markets to provide financial firepower for its pipeline of biosimilar candidates.
Viatris To Shed OTC, APIs And Women’s Health As Biocon Deal Nears Completion
Viatris has marked an important inflection point in its short life, announcing several more planned divestitures alongside the proposed acquisition of a pair of eyecare companies for up to $750m in cash.